Neogenomics Inc: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 6, 2023 and accepted by EDGAR at Nov 6, 2023, 21:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $152.0m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $436.1m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $89.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-01-01 to 2023-09-30 | $259.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $62.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-01-01 to 2023-09-30 | $177.0m | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $5.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $20.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$24.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$89.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | −$2.8m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | −$6.8m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | −$2.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | −$8.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$18.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$73.6m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 125,687,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 125,358,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$19.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $21.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-09-30 | $306.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $587.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $1.68bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $92.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $730.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | $947.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001077183-23-000138. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.